The New Joseph Edelman’s Perceptive Advisors Llc Holding in Versartis, Inc
Perceptive Advisors Llc filed with the SEC SC 13G/A form for Versartis, Inc. The form can be accessed here: 000101905616001573. As reported in Joseph Edelman’s Perceptive Advisors Llc’s form, the filler as of late owns 13.63% or 4,028,685 shares of the Health Care–company.
Versartis, Inc stake is a new one for the for the hedge fund and it was filed because of activity on September28, 2016. We feel this shows Joseph Edelman’s Perceptive Advisors Llc’s positive view for the stock. For a hedge fund managing $2.09 billion in assets and having 13+ active experts, we at Financialmagazine have no doubt the buy is a bullish signal.
The hedge fund is active investor in the Health Care sector. In the manager’s last 13-F, we saw 12% of Joseph Edelman’s Perceptive Advisors Llc’s US equities portfolio is in this sector.
Versartis, Inc Institutional Sentiment
Latest Security and Exchange filings show 60 investors own Versartis, Inc. The institutional ownership in Q3 2015 is high, at 61.37% of the outstanding shares. This is increased by 714558 the total institutional shares. 21135743 were the shares owned by these institutional investors. In total 10 funds opened new Versartis, Inc stakes, 27 increased stakes. There were 15 that closed positions and 14 reduced them.
3 managers had the stock in their top Ten. Notable investors are: New Leaf Venture Partners L.L.C., Aisling Capital Llc, Perceptive Advisors Llc..
Julian Baker And Felix Baker Baker Bros Advisors Lp is an institutional investor bullish on Versartis, Inc, owning 3241783 shares as of Q3 2015 for 0.35% of its portfolio. Joseph Edelman Perceptive Advisors Llc owns 2317954 shares or 2.14% of its portfolio. NY New Leaf Venture Partners Llc have 20.39% of their stock portfolio for 2039223 shares. Further, Aisling Capital Llc reported stake worth 4.62% of its US stock portfolio. The CA First Republic Investment Management Inc owns 48380 shares. Versartis, Inc is 0.01% of the manager’s US portfolio.
Versartis, Inc. is an endocrine-focused biopharmaceutical company. The Company is engaged in developing long-acting recombinant human growth hormone (rhGH), somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s product pipeline includes VRS-317 and XTEN Technology. The Company’s VRS-317 combines the rhGH amino acid sequence utilized in approved rhGH products with a half-life extension technology, XTEN, to enable less frequent administration. The XTEN technology consists of hydrophilic amino acids added at the genetic level as part of the manufacturing process. The Company’s XTEN is a recombinant polypeptide designed to extend the in vivo half-life of peptides and proteins in a tunable manner. The XTEN sequence consists of hydrophilic amino acids and possesses various additional properties, which are used for the development of protein pharmaceuticals.
SEC Form 13G is required when the filer owns between (5% and 20%) of a company and plans to hold it only as a passive investor. In case the filler intend to exert control and the stake’s exceeds 20%, then 13D Form must be filed. These filings can NOT be a precursor to “change of control” events such as hostile takeovers, company breakups or others.
Joseph Edelman’s Perceptive Advisors Llc website.
Insitutional Activity: The institutional sentiment increased to 3 in Q2 2016. Its up 1.93, from 1.07 in 2016Q1. The ratio increased, as 5 funds sold all Versartis Inc shares owned while 8 reduced positions. 5 funds bought stakes while 34 increased positions. They now own 20.36 million shares or 0.09% more from 20.34 million shares in 2016Q1.
Morgan Stanley has invested 0% of its portfolio in Versartis Inc (NASDAQ:VSAR). Legal & General Grp Public Limited Com holds 4,502 shares or 0% of its portfolio. Metropolitan Life Company Ny accumulated 0% or 18,987 shares. Barclays Public last reported 0% of its portfolio in the stock. Alliancebernstein Lp has 0% invested in the company for 12,800 shares. D E Shaw And has 26,051 shares for 0% of their US portfolio. Goldman Sachs Group holds 0% or 20,821 shares in its portfolio. Swiss Bank & Trust accumulated 0% or 35,400 shares. Moreover, Deutsche Bancorp Ag has 0% invested in Versartis Inc (NASDAQ:VSAR) for 6,976 shares. Teacher Retirement Systems Of Texas last reported 0% of its portfolio in the stock. Jacobs Levy Equity Mgmt Inc accumulated 102,888 shares or 0.02% of the stock. Nationwide Fund Advsr holds 56,765 shares or 0% of its portfolio. Art Advsrs Ltd holds 0.01% of its portfolio in Versartis Inc (NASDAQ:VSAR) for 17,547 shares. Parametric Port Assocs Limited Liability Company holds 47,728 shares or 0% of its portfolio. Geode Capital Mngmt Limited Liability accumulated 0% or 146,587 shares.
Insider Transactions: Since April 21, 2016, the stock had 1 buying transaction, and 6 insider sales for $6.86 million net activity. Westberg Paul sold $7,707 worth of Versartis Inc (NASDAQ:VSAR) on Wednesday, June 15. 1,600 Versartis Inc (NASDAQ:VSAR) shares with value of $20,755 were sold by Varian John. $15,392 worth of Versartis Inc (NASDAQ:VSAR) shares were sold by Brumm Joshua T. $7.00M worth of shares were bought by AKKARAJU SRINIVAS on Monday, October 3. Shares for $70,093 were sold by Shepard Jay on Monday, August 22.
Analysts await Versartis Inc (NASDAQ:VSAR) to report earnings on November, 3. They expect $-0.84 EPS, down 21.74% or $0.15 from last year’s $-0.69 per share. After $-0.75 actual EPS reported by Versartis Inc for the previous quarter, Wall Street now forecasts 12.00% negative EPS growth.
About 131,523 shares traded hands. Versartis Inc (NASDAQ:VSAR) has risen 59.08% since March 2, 2016 and is uptrending. It has outperformed by 50.83% the S&P500.
Versartis, Inc. is an endocrine-focused biopharmaceutical company. The company has a market cap of $414.64 million. The Firm is engaged in developing long-acting recombinant human growth hormone , somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. It currently has negative earnings. The Company’s product pipeline includes VRS-317 and XTEN Technology.
Versartis Inc (NASDAQ:VSAR) Ratings Coverage
Out of 6 analysts covering Versartis Inc (NASDAQ:VSAR), 4 rate it a “Buy”, 1 “Sell”, while 1 “Hold”. This means 67% are positive. $23 is the highest target while $17 is the lowest. The $20 average target is 66.39% above today’s ($12.02) stock price. Versartis Inc has been the topic of 8 analyst reports since August 13, 2015 according to StockzIntelligence Inc. On Thursday, August 13 the stock rating was initiated by Morgan Stanley with “Equal Weight”. Northland Capital initiated Versartis Inc (NASDAQ:VSAR) on Thursday, April 7 with “Outperform” rating. On Tuesday, October 4 the stock rating was initiated by Piper Jaffray with “Overweight”. The rating was maintained by Citigroup with “Buy” on Thursday, August 11. Credit Suisse downgraded the shares of VSAR in a report on Thursday, December 17 to “Underperform” rating. The firm has “Neutral” rating by Credit Suisse given on Thursday, August 20. The rating was maintained by Canaccord Genuity on Monday, September 21 with “Buy”.
More recent Versartis Inc (NASDAQ:VSAR) news were published by: Quotes.Wsj.com which released: “Versartis Inc. VSAR (US: Nasdaq)” on March 21, 2014. Also Marketwatch.com published the news titled: “Virtual Stock Exchange” on March 21, 2014. Benzinga.com‘s news article titled: “Versartis Reports Data from Up to 30 Mos. of Somavaratan Treatment for …” with publication date: September 12, 2016 was also an interesting one.
According to Zacks Investment Research, “Versartis, Inc. operates as a biotechnology company. It develops therapeutic proteins for the treatment of metabolic diseases and endocrine disorders. The Company is developing VRS-317, a long-acting recombinant human growth hormone, which is in Phase 2a clinical trials for the treatment of growth hormone deficiency. Versartis, Inc. is headquartered in Redwood City, California.”
VSAR Company Profile
Versartis, Inc., incorporated on December 10, 2008, is an endocrine-focused biopharmaceutical company. The Firm is engaged in developing long-acting recombinant human growth hormone (rhGH), somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s product pipeline includes VRS-317 and XTEN Technology.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.